Price Alert

Xeris Biopharma Inc. (XERS)

NASDAQ: XERS · Real-Time Price · USD

7.85

-0.04 (-0.51%)

At close: Sep 05, 2025, 3:59 PM

7.86

0.13%

After-hours: Sep 05, 2025, 07:49 PM EDT

-0.51% (1D)

Bid	7.75
Market Cap	1.27B
Revenue (ttm)	246.03M
Net Income (ttm)	-32M
EPS (ttm)	-0.2
PE Ratio (ttm)	-39.25
Forward PE	31.36
Analyst	Buy

Ask	7.97
Volume	1,504,602
Avg. Volume (20D)	2,428,093
Open	7.92
Previous Close	7.89
Day's Range	7.75 - 7.96
52-Week Range	2.49 - 8.03
Beta	0.86

About XERS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol XERS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for XERS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Xeris Biopharma Inc. is scheduled to release its earnings on Nov 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+20.22%

Xeris Biopharma Holdings shares are trading higher... Unlock content with Pro Subscription

3 months ago

-7.92%

Xeris Biopharma Holdings shares are trading lower. The company released Its strategy for long-term growth and value creation at 2025 analyst & investor day.

News

17 hours ago · seekingalpha.com

Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy

Xeris Biopharma delivered record Q2 revenue, driven by Recorlev's rapid adoption, and is on track to achieve breakeven in Q3. Recorlev is the primary growth engine, while Gvoke provides steady diversi...

1 week ago · businesswire.com

Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...

3 weeks ago · zacks.com

Xeris Biopharma (XERS) Upgraded to Buy: Here's Why

Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 weeks ago · zacks.com

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

4 weeks ago · seekingalpha.com

Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Comm...

4 weeks ago · fool.com

Xeris (XERS) Q2 Revenue Jumps 49%

4 weeks ago · zacks.com

Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street e...

4 weeks ago · zacks.com

Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates

Xeris Biopharma (XERS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.1 per share a year ago.